WHEN IT COMES
TO CONTRACEPTION,
let’s make
it personal.

Prescribe Phexxi®—a first-in-class, non-hormonal birth
control that can meet the individual needs of women.1

How Phexxi Works

Phexxi non-hormonal birth control gel applicator

What is
Phexxi?

Phexxi is a vaginal contraceptive gel for women who are simply seeking pregnancy prevention without the use of hormones. It is the only vaginal pH modulator (VPM) that works by maintaining an acidic vaginal pH and decreasing sperm motility.2

How Phexxi Works

microsope icon

Proven to prevent pregnancy

Phexxi is a safe and effective contraceptive, clinically proven to prevent pregnancy.
86% effective with typical use.3
93% effective with perfect use.4
Female symbol icon

Who is right for Phexxi?

Women who are simply seeking pregnancy prevention.
Phexxi gel icon

Phexxi is easy to use and prescribe5

In fact, 93% of women would recommend Phexxi to a friend3
Dollar sign icon

Phexxi Savings Program

Phexxi may be available at a discounted price!

References:

  1. Phexxi® Vaginal Gel. Medi-Span®; June 8, 2020.
  2. Phexxi® [Prescribing Information]. Evofem Biosciences, Inc.: San Diego, CA; June 2023.
  3. Thomas MA, Chappell BT, Maximos B, Culwell KR, Dart C, Howard B. A novel vaginal pH regulator; results from the phase 3 AMPOWER contraception clinical trial. Contracept X. 2020;2:100031.
  4. Chappell BT, Culwell K, Dart C, Howard B. Perfect-use pregnancy rates with the vaginal pH regulator: efficacy results from AMPOWER [30I]. Obstet Gynecol. 2020;135:99S.
  5. Data on file. Evofem Biosciences, Inc.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Few cases (0.36%) of adverse reactions of cystitis, pyelonephritis and other upper urinary tract infection (UTI) have been reported in Phexxi clinical studies. Of these, one case of pyelonephritis was considered serious and required hospitalization. Avoid use of Phexxi in females with history of recurrent urinary tract infection or urinary tract abnormalities.

ADVERSE REACTIONS

Most common adverse reactions were vulvovaginal burning sensation, pruritus, mycotic infection, genital discomfort (including male partners); urinary tract infection, bacterial vaginosis, vaginal discharge, and dysuria. Patients should consult their healthcare provider for severe or prolonged genital irritation or urinary tract symptoms.

Advise the patient:

  • To discontinue Phexxi if they develop a local hypersensitivity reaction.
  • That Phexxi does not protect against HIV infection or other sexually transmitted infections.
  • Avoid Phexxi use with vaginal rings.

To report SUSPECTED ADVERSE REACTIONS, contact Evofem at toll-free phone 1-833-EVFMBIO or you may contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for Phexxi.

INDICATION

Phexxi is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.

LIMITATIONS OF USE

Phexxi is not effective for the prevention of pregnancy when administered after intercourse.

References:

  1. Phexxi® Vaginal Gel. Medi-Span®; June 8, 2020.
  2. Phexxi® [Prescribing Information]. Evofem Biosciences, Inc.: San Diego, CA; June 2023.
  3. Thomas MA, Chappell BT, Maximos B, Culwell KR, Dart C, Howard B. A novel vaginal pH regulator; results from the phase 3 AMPOWER contraception clinical trial. Contracept X. 2020;2:100031.
  4. Chappell BT, Culwell K, Dart C, Howard B. Perfect-use pregnancy rates with the vaginal pH regulator: efficacy results from AMPOWER [30I]. Obstet Gynecol. 2020;135:99S.
  5. Data on file. Evofem Biosciences, Inc.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Few cases (0.36%) of adverse reactions of cystitis, pyelonephritis and other upper urinary tract infection (UTI) have been reported in Phexxi clinical studies. Of these, one case of pyelonephritis was considered serious and required hospitalization. Avoid use of Phexxi in females with history of recurrent urinary tract infection or urinary tract abnormalities.

ADVERSE REACTIONS

Most common adverse reactions were vulvovaginal burning sensation, pruritus, mycotic infection, genital discomfort (including male partners); urinary tract infection, bacterial vaginosis, vaginal discharge, and dysuria. Patients should consult their healthcare provider for severe or prolonged genital irritation or urinary tract symptoms.

Advise the patient:

  • To discontinue Phexxi if they develop a local hypersensitivity reaction.
  • That Phexxi does not protect against HIV infection or other sexually transmitted infections.
  • Avoid Phexxi use with vaginal rings.

To report SUSPECTED ADVERSE REACTIONS, contact Evofem at toll-free phone 1-833-EVFMBIO or you may contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for Phexxi.

INDICATION

Phexxi is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.

LIMITATIONS OF USE

Phexxi is not effective for the prevention of pregnancy when administered after intercourse.